Credence MedSystems Brand Guidelines: Menlo Park’s Companion Syringe & Dual Chamber

A syringe idea for drug makers, not pharmacies.

Credence MedSystems is a drug delivery company based in Menlo Park, California, where its press releases are datelined. It does not sell to patients or pharmacies: it designs injection systems for pharmaceutical and biotechnology manufacturers, which fill them with their own medicines. The company calls its approach “Innovation Without Change”, a phrase it carries as a registered mark, and says its systems are built on existing prefilled syringes and standard components, so that drug makers can keep their sourcing, filling processes and validated parts.

Its first product went public in September 2014. A Business Wire release from Menlo Park announced the Credence Companion Safety Syringe System, launched at two drug delivery conferences, and quoted Jeff Shanley as chief executive. The release said the Companion was built around an existing prefilled syringe and standard drug container components, so a manufacturer could choose a syringe from any vendor and keep its filling process unchanged. In use, the company said, the needle retracts automatically into the barrel after the injection and the syringe is then disabled.

The first independent coverage came with funding. On 13 September 2016 Drug Delivery Business News reported that Credence had raised a Series A round to fund the development and commercialisation of its injectable drug delivery device. The publication called the Companion the company’s flagship, a pre-fillable device sold to drug manufacturers, and summarised how it works: the user gets a cue at the end of the dose and the needle retracts into the syringe. It reported Credence’s statement that the system worked with commercially available syringe barrels and closure components, and quoted Jeff Tillack, then chief operating officer, and John Merhige, chief commercial officer, who said the company had several active collaborations with multinational pharmaceutical and biotechnology manufacturers.

The same two executives now lead it. The company’s leadership page names Merhige and Tillack as co-chief executives, Merhige in charge of business development, sales and marketing and Tillack of development, quality, regulatory affairs and operations. It says Merhige came from Sanofi BioSurgery, which he joined when Sanofi acquired Pluromed in 2012, and that Tillack had held operations roles at Calibra Medical and Conor Medsystems.

From one syringe to a family of systems.

The range has grown from one syringe into a family. The Credence website groups it into the Companion product family, with a staked needle syringe and a Luer syringe; the Dual Chamber Syringe; metered dosing products, namely the Micro-Dose and Multi-Site syringe systems and Force-Assist; and connected health products, the Credence Connect auto-sensing injection system and a smart electronic autoinjector. A September 2026 company release describes the Companion line-up as running from 1 mL to 5 mL.

The Dual Chamber system answers a formulation question. The company’s January 2024 release describes a Dual Chamber Sequential Syringe that stores two liquid drug products separately in one syringe barrel and delivers them in a single injection, and a 2026 release says the dual chamber design allows either reconstitution or the sequential injection of two liquids. In October 2019 Credence announced a grant from the Gates Foundation to advance a dual chamber device for global health settings.

The Micro-Dose system deals in very small volumes. The company’s release of 7 January 2026 announced a commercial supply agreement with an unnamed global biopharmaceutical company working in intra-ocular therapy, under which Credence would develop, manufacture and supply its ophthalmic injection device for one programme. The same release described its metered dosing devices as designed for single or multiple injections of microlitre volumes in ophthalmology and medical aesthetics.

Industry juries have recognised the designs, according to the company’s awards page. The Companion won an award for the best and most innovative advancement in drug delivery at the Drug Delivery Partnerships meeting in Boca Raton in January 2015; Credence took the Innovation First Prize at Pharmapack Europe in Paris in February 2015; it received an “On-The-Rise” award at Drug Delivery Partnerships in January 2018; and it won Best Innovation in Drug Delivery at Pharmapack in Paris in February 2020.

How drug delivery makers present themselves.

Drug-delivery device makers sell mostly to other companies. Their customers are pharmaceutical and biotech firms that fill a pen, an autoinjector or a prefilled syringe with their own medicine and put their own name on the box, so the device maker’s brand often lives one step back from the patient. That shapes how these companies present themselves: less as consumer brands, more as engineering partners that can be trusted with a drug company’s product.

The pictures follow from that. The typical image is a clean render of a pen or autoinjector on a white or pale ground, often shown from several angles or in a technical cutaway that reveals the spring, the plunger and the syringe inside. Product families are usually named as platforms, with one prefix running across a range, and shown in neutral greys and whites so that a customer can imagine its own colours on the device.

Production is the other recurring theme. Websites and brochures show cleanroom assembly lines, injection-moulding machines, operators in gowns and hairnets, and gloved hands holding glass syringes, cartridges and vials. These images carry the message that the work is precise and controlled, and they sit beside pages on quality systems, regulatory support and human-factors testing with patients.

Much of the industry’s public face is seen at trade shows. Makers book stands at events such as CPHI, the pharmaceutical ingredients and packaging fair, Pharmapack in Paris, and the conferences of the Parenteral Drug Association, where they show new platforms to drug companies. The visual language there is the same: white stands, large product renders, cutaway models and short films of devices being assembled and used.

Investors, a contract maker and a quality milestone.

Credence has relied on partners to scale. In January 2021 it announced that Novartis had made a strategic investment, aimed at building up manufacturing capacity with an initial focus on the Companion; the same release mentioned a collaboration with SCHOTT AG to apply Companion technology to SCHOTT’s pre-fillable glass and polymer syringes. The company’s press page lists further financing rounds in 2018 and 2021.

Manufacturing runs through a contract maker. Credence announced a strategic collaboration with Phillips-Medisize in October 2021. In January 2024 it said it had completed factory acceptance testing of a Clinical Assembly Line, built by Mikron Automation on its MiniCell platform in Denver, which was to move to the Phillips-Medisize plant at Letterkenny, Ireland, for ongoing production. The company said the line was designed to produce about 500,000 units a year of the Companion and Dual Chamber systems, for device verification, drug stability studies and clinical trials, and quoted Merhige as saying Credence worked with two-thirds of the world’s 20 largest pharmaceutical and biologics manufacturers.

The latest milestone concerns quality systems. On 29 September 2026 Credence announced that its quality management system had been certified to ISO 13485:2016, with the certificate issued by BSI, and described the step as part of becoming a ready-to-supply partner for its pharmaceutical and biotech customers. Its homepage now leads with the ophthalmic supply agreement announced at the start of the year.

Across its releases the company repeats a small vocabulary: Companion, Dual Chamber, Micro-Dose and the phrase “Innovation Without Change,” which appears on its homepage, its about page and its press releases.

For a design guide, Credence MedSystems shows how a supplier that works behind pharmaceutical brands can build an identity on one idea: keep the familiar syringe and change what surrounds it. Compare Phillips-Medisize, its manufacturing partner in Ireland, and BD, the American medical technology company. For this guide we use a deep pine green, a soft sage and a pale linen with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Credence MedSystems’s identity on hand — save it to a board in the Made Good inspiration library.